Tamoxifen in breast cancer can be continued for 10 years with increased benefit but endometrial cancer can develop in treated patients. We report a case of poorly differentiated endometrioid adenocarcinoma, which developed in a woman with history of tamoxifen intake of over five years after breast cancer, who did not undergo any endometrial surveillance.
Key words: Tamoxifen, endometrial carcinoma, breast cancer
|
